TP53 and non-small cell lung carcinoma: First, despite NFE2L2-mutated NSCLC being marked by changes in signaling pathways, such as in interferon response, inflammatory, JAK STAT3, p53, mTORC1, and ROS, the molecular basis of NFE2L2 MUs associated with ICI response remained unclear and required experimental research.